Form 8-K - Current report:
SEC Accession No. 0001193125-24-208814
Filing Date
2024-08-28
Accepted
2024-08-28 16:15:31
Documents
16
Period of Report
2024-08-01
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d833928d8k.htm   iXBRL 8-K 32460
2 EX-99.1 d833928dex991.htm EX-99.1 19783
6 GRAPHIC g833928g0828021636131.jpg GRAPHIC 631
7 GRAPHIC g833928g35v91.jpg GRAPHIC 12771
  Complete submission text file 0001193125-24-208814.txt   199351

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rptx-20240801.xsd EX-101.SCH 2511
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rptx-20240801_lab.xml EX-101.LAB 18665
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rptx-20240801_pre.xml EX-101.PRE 11672
18 EXTRACTED XBRL INSTANCE DOCUMENT d833928d8k_htm.xml XML 3906
Mailing Address 7171 FREDERICK BANTING SUITE 270, BUILDING 2 SAINT-LAURENT A8 H4S 1Z9
Business Address 7171 FREDERICK BANTING SUITE 270, BUILDING 2 SAINT-LAURENT A8 H4S 1Z9 (857) 412-7018
Repare Therapeutics Inc. (Filer) CIK: 0001808158 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39335 | Film No.: 241255661
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)